drug pricing

Regeneron agrees with Trump Administration to lower drug prices via Medicaid benchmarking and free gene therapy access, receiving three years of tariff relief and regulatory certainty.

Regeneron offers gene therapy Otarmeni free and Praluent at lower pricing in exchange for tariff relief and exemption from future pricing mandates.

Ionis Pharmaceuticals cuts Tryngolza price from $595K to $40K annually, positioning for broader FDA approval and potential $2B+ peak sales.

Over 40 Indian pharma companies launched generic semaglutide after patent expiration, pricing treatments 70% below Novo Nordisk's originals. Market expansion planned globally.

Oral weight-loss drugs expand the market rather than cannibalizing injectables, attracting new patients. However, Novo Nordisk expects 2026 revenue headwinds from competition and pricing pressures.